Clinical trial
Open Label Study (Everyone Who Participates Receives Drug) to Further Determine…
NCT00175864 · UCB Pharma, Industry · Withdrawn
Key facts
| NCT number | NCT00175864 |
|---|---|
| Title | Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy. |
| Official title | Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (Ucb 44212) at Individualized Doses up to a Maximum of 160mg/Day in Refractory Epileptic Patients. |
| Lead sponsor | UCB Pharma, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | Seletracetam (ucb 44212) |
| Enrollment | 0 |
| Start date | Feb 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Mar 20, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: